Shared on 16 Sep 25
Fair value Increased 1k%FDA Alignment And Phase 3 Trials Will Advance AMD Therapy
Despite a significant increase in the consensus analyst price target from $4.00 to $60.00, analysts remain cautious due to Clearside's uncertain strategic direction, tough financing environment, and diminishing cash runway, which cloud visibility into the company's future. Analyst Commentary Announcement of exploring strategic alternatives created uncertainty around Clearside's future direction.
Shared on 01 May 25
Fair value Decreased 69%FDA Alignment And Phase 3 Trials Will Advance AMD Therapy
Shared on 24 Apr 25
FDA Alignment And Phase 3 Trials Will Advance AMD Therapy
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Fair value Increased 139%FDA Alignment And Phase 3 Trials Will Advance AMD Therapy
AnalystConsensusTarget has increased revenue growth from 93.5% to 129.7%, increased future PE multiple from 104.5x to 148.3x and decreased shares outstanding growth rate from 0.0% to 0.0%.